

The Maudsley

Guidelines on
Advanced
Prescribing in
Psychosis

Paul Morrison
David M. Taylor
Phillip McGuire

WILEY Blackwell

**Advanced
Prescribing
in Psychosis**

The Maudsley Guidelines on Advanced Prescribing in Psychosis

Paul Morrison

Argyll and Bute Hospital
Scotland, UK
and
Institute of Psychiatry
Psychology and Neuroscience
King's College London
London, UK

David M. Taylor

Maudsley Hospital
and
King's College London
London, UK

Phillip McGuire

Institute of Psychiatry
Psychology and Neuroscience
King's College London
London, UK

WILEY Blackwell

This edition first published 2020
© 2020 John Wiley & Sons Ltd

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of Paul Morrison, David M. Taylor and Phillip McGuire to be identified as the authors of this work has been asserted in accordance with law.

Registered Offices

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA
John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial Office

111 River Street, Hoboken, NJ 07030, USA

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

Limit of Liability/Disclaimer of Warranty

While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Cataloging-in-Publication Data

Names: Morrison, Paul, 1956– author. | Taylor, David M., 1963– author. | McGuire, Philip, author.

Title: The Maudsley guidelines on advanced prescribing in psychosis / Paul Morrison, David M. Taylor, Phillip McGuire.

Other titles: Guidelines on advanced prescribing in psychosis

Description: Hoboken, NJ : Wiley-Blackwell, 2020. | Includes bibliographical references and index.

Identifiers: LCCN 2019047707 (print) | LCCN 2019047708 (ebook) | ISBN 9781119578444 (paperback) | ISBN 9781119578529 (adobe pdf) | ISBN 9781119578437 (epub)

Subjects: MESH: Psychotic Disorders—drug therapy | Antipsychotic Agents—side effects | Evidence-Based Medicine | Physician-Patient Relations | Treatment Outcome

Classification: LCC RC483 (print) | LCC RC483 (ebook) | NLM WM 200 | DDC 616.89/18—dc23

LC record available at <https://lccn.loc.gov/2019047707>

LC ebook record available at <https://lccn.loc.gov/2019047708>

Cover Design: Wiley

Set in 10/12pt Sabon by SPi Global, Pondicherry, India

Contents

List of tables	ix
Preface	xi
Glossary	xiii
Acknowledgments	xv
Chapter 1 Psychosis	1
1.1 What is psychosis?	1
1.2 Lack of insight	1
1.3 Causes of psychosis	2
1.4 Schizophrenia: loss of personality and psychosocial decline	2
1.5 Bipolar disorder	3
1.6 Cannabis, synthetic cannabinoids, and psychosis	4
Chapter 2 Towards evidence based treatments for psychosis	7
2.1 Traditional medicine	7
2.2 The randomised controlled trial	7
2.3 The roots of community care	8
2.4 Treatment algorithms versus personalised care	8
Chapter 3 The antipsychotics	9
3.1 General principles in the pharmacology of psychosis	9
3.2 Neurotransmitters and receptors	10
3.3 Choosing drugs	12
3.4 Acute psychotic episodes	13
3.4.1 Olanzapine in acute psychotic episodes	15
3.4.2 Antipsychotic dosing in acute psychotic episodes	15
3.4.3 Timescale of response in acute psychotic episodes	17
3.4.4 Very agitated patients	17
3.5 The maintenance phase: relapse prevention	18
3.5.1 Beyond the early years: more harm than good?	18
3.6 The utility of long-acting depot antipsychotics	22
3.7 Principles of long-acting depot antipsychotic prescribing	23
3.7.1 Clozapine	25
3.7.2 Clozapine resistant psychosis	26

3.7.3	Side effects of clozapine	27
3.7.4	Myocarditis: inflammation of heart muscle	28
3.7.5	Cardiomyopathy: impaired function of heart muscle	29
3.7.6	The effects of clozapine at muscarinic M1–M4 acetylcholine receptors	29
3.7.7	Weight-gain and type II diabetes	30
3.7.8	Neutropenia and agranulocytosis	30
3.7.9	Lowered seizure threshold	31
Chapter 4	Bipolar disorder	33
4.1	Diagnosis of bipolar	33
4.2	Treatment of mania	34
4.3	Treatment of bipolar depression	34
4.4	The maintenance phase of bipolar: relapse prevention	39
4.5	Bipolar in females of childbearing age	41
4.5.1	Valproate and carbamazepine in females of childbearing age	41
4.5.2	Lithium in females of childbearing age	41
4.5.3	Lamotrigine in females of childbearing age	42
4.5.4	Antipsychotics in females of childbearing age	42
Chapter 5	The role of talking therapies in the treatment of psychosis	43
5.1	Psychoanalytical insights	43
5.2	Psychological treatments	43
Chapter 6	Side effects of antipsychotic treatment	45
6.1	Weight gain	45
6.1.1	Antipsychotics at 5HT _{2c} receptors	45
6.1.2	The management of weight gain and obesity	46
6.2	Type II diabetes	46
6.3	Dyslipidemia	48
6.3.1	The management of dyslipidemia in psychosis services	48
6.4	Motor side effects	49
6.4.1	Tardive dyskinesia	51
6.4.2	First versus second generation	51
6.5	Hyperprolactinemia	51
6.5.1	The management of hyperprolactinemia	52
6.6	Sexual side effects	52
6.6.1	Management	53
6.7	Prolonged QTc	53
6.7.1	Calculating the QTc	53
6.7.2	QTc thresholds	54
6.7.3	Torsades de points	54
6.7.4	Antipsychotics and QTc prolongation	54
6.7.5	Management	55
6.8	Neuroleptic malignant syndrome	55
6.8.1	Management	56

Chapter 7	Services: pathway specific care	57
	7.1 Background	57
	7.2 The at-risk-mental-state	57
	7.3 Early intervention services	58
	7.4 Acute services	59
	7.5 Continuing care services: promoting recovery	59
Chapter 8	Measuring outcomes	61
	8.1 Value-based healthcare	61
	8.2 Evidence-based healthcare management (EBMGT)	62
Appendix 1	Pharmacokinetics of selected psychotropics	65
Appendix 2	The metabolic syndrome	71
Appendix 3	Physical health monitoring for patients prescribed antipsychotics	73
Appendix 4	Physical health monitoring for patients prescribed mood stabilisers	75
	References	77
	Index	91

List of tables

3.1	General principles in the pharmacology of psychosis	10
3.2	Comparative receptor affinity of commonly prescribed antipsychotics	11
3.3	Antipsychotics for an acute psychotic episode	14
3.4	Adjunctive medication for an acute psychotic episode	16
3.5	Rapid tranquillisation	17
3.6	Clopixol acuphase (zuclopenthixol acetate)	18
3.7	Antipsychotics for the maintenance phase	19
3.8	Long-acting depot preparations	24
3.9	Clozapine and neutrophil counts in the UK	31
4.1	Drug treatment of bipolar disorder	35
6.1	Thresholds for diabetes	47
6.2	Extra-pyramidal side effects	50
8.1	Outcome rating scales	62
Appendix 1: Pharmacokinetics of selected psychotropics		65
Appendix 2: The metabolic syndrome		71
Appendix 3: Physical health monitoring for patients prescribed antipsychotics		73
Appendix 4: Physical health monitoring for patients prescribed mood stabilisers		75

